Javier Bachiller-Corral1, Alina Boteanu2, Maria Jesus Garcia-Villanueva3, Carlos de la Puente3, Marcelino Revenga4, M Consuelo Diaz-Miguel3, Ana Rodriguez-Garcia3, Jose Luis Morell-Hita3, Marta Valero3, Carmen Larena3, Maria Blazquez-Cañamero3, Carlos A Guillen-Astete3, Sandra Garrote3, Cristina Sobrino3, Carmen Medina-Quiñones3, Mónica Vazquez-Diaz2. 1. J. Bachiller-Corral, MD, Assistant Head, A. Boteanu, MD, Assistant Head, M. Vazquez-Diaz, MD, Department Head, Department of Rheumatology, Hospital Universitario Ramón y Cajal, and Irycis (Instituto Ramón y Cajal de investigación sanitaria), Madrid; fbachiller@salud.madrid.org. 2. J. Bachiller-Corral, MD, Assistant Head, A. Boteanu, MD, Assistant Head, M. Vazquez-Diaz, MD, Department Head, Department of Rheumatology, Hospital Universitario Ramón y Cajal, and Irycis (Instituto Ramón y Cajal de investigación sanitaria), Madrid. 3. M.J. Garcia-Villanueva, MD, Assistant Head, C. de la Puente, MD, Assistant Head, M.C. Diaz-Miguel, MD, Assistant Head, A. Rodriguez-Garcia, MD, Assistant Head, J.L. Morell-Hita, MD, Assistant Head, M. Valero, MD, Assistant Head, C. Larena, MD, Assistant Head, M. Blazquez-Cañamero, MD, Assistant Head, C.A. Guillen-Astete, MD, PhD, Assistant Head, S. Garrote, MD, Assistant Head, C. Sobrino, MD, Assistant Head, C. Medina-Quiñones, MD, Assistant Head, Department of Rheumatology, Hospital Universitario Ramón y Cajal, Madrid. 4. M. Revenga, MD, PhD, Department of Rheumatology, Hospital Universitario Ramón y Cajal, Madrid, and Facultad de Medicina. Universidad de Alcalá, Alcalá de Henares, Spain.
Abstract
OBJECTIVE: To describe the cohort of patients with inflammatory rheumatic diseases (IRD) hospitalized due to SARS-CoV-2 infection in the Ramón y Cajal Hospital, and to determine the increased risk of severe coronavirus disease 2019 (COVID-19) in patients with no IRD. METHODS: This is a retrospective single-center observational study of patients with IRD actively monitored in the Department of Rheumatology who were hospitalized due to COVID-19. RESULTS: Forty-one (1.8%) out of 2315 patients admitted due to severe SARS-CoV-2 pneumonia suffered from an IRD. The admission OR for patients with IRD was 1.91 against the general population, and it was considerably higher in patients with Sjögren syndrome, vasculitis, and systemic lupus erythematosus. Twenty-seven patients were receiving treatment for IRD with corticosteroids, 23 with conventional DMARDs, 12 with biologics (7 rituximab [RTX], 4 anti-tumor necrosis factor [anti-TNF], and 1 abatacept), and 1 with Janus kinase inhibitors. Ten deaths were registered among patients with IRD. A higher hospitalization rate and a higher number of deaths were observed in patients treated with RTX (OR 12.9) but not in patients treated with anti-TNF (OR 0.9). CONCLUSION: Patients with IRD, especially autoimmune diseases and patients treated with RTX, may be at higher risk of severe pneumonia due to SARS-CoV-2 compared to the general population. More studies are needed to analyze this association further in order to help manage these patients during the pandemic.
OBJECTIVE: To describe the cohort of patients with inflammatory rheumatic diseases (IRD) hospitalized due to SARS-CoV-2 infection in the Ramón y Cajal Hospital, and to determine the increased risk of severe coronavirus disease 2019 (COVID-19) in patients with no IRD. METHODS: This is a retrospective single-center observational study of patients with IRD actively monitored in the Department of Rheumatology who were hospitalized due to COVID-19. RESULTS: Forty-one (1.8%) out of 2315 patients admitted due to severe SARS-CoV-2 pneumonia suffered from an IRD. The admission OR for patients with IRD was 1.91 against the general population, and it was considerably higher in patients with Sjögren syndrome, vasculitis, and systemic lupus erythematosus. Twenty-seven patients were receiving treatment for IRD with corticosteroids, 23 with conventional DMARDs, 12 with biologics (7 rituximab [RTX], 4 anti-tumor necrosis factor [anti-TNF], and 1 abatacept), and 1 with Janus kinase inhibitors. Ten deaths were registered among patients with IRD. A higher hospitalization rate and a higher number of deaths were observed in patients treated with RTX (OR 12.9) but not in patients treated with anti-TNF (OR 0.9). CONCLUSION: Patients with IRD, especially autoimmune diseases and patients treated with RTX, may be at higher risk of severe pneumonia due to SARS-CoV-2 compared to the general population. More studies are needed to analyze this association further in order to help manage these patients during the pandemic.
Authors: Zara Izadi; Milena A Gianfrancesco; Alfredo Aguirre; Anja Strangfeld; Elsa F Mateus; Kimme L Hyrich; Laure Gossec; Loreto Carmona; Saskia Lawson-Tovey; Lianne Kearsley-Fleet; Martin Schaefer; Andrea M Seet; Gabriela Schmajuk; Lindsay Jacobsohn; Patricia Katz; Stephanie Rush; Samar Al-Emadi; Jeffrey A Sparks; Tiffany Y-T Hsu; Naomi J Patel; Leanna Wise; Emily Gilbert; Alí Duarte-García; Maria O Valenzuela-Almada; Manuel F Ugarte-Gil; Sandra Lúcia Euzébio Ribeiro; Adriana de Oliveira Marinho; Lilian David de Azevedo Valadares; Daniela Di Giuseppe; Rebecca Hasseli; Jutta G Richter; Alexander Pfeil; Tim Schmeiser; Carolina A Isnardi; Alvaro A Reyes Torres; Gelsomina Alle; Verónica Saurit; Anna Zanetti; Greta Carrara; Julien Labreuche; Thomas Barnetche; Muriel Herasse; Samira Plassart; Maria José Santos; Ana Maria Rodrigues; Philip C Robinson; Pedro M Machado; Emily Sirotich; Jean W Liew; Jonathan S Hausmann; Paul Sufka; Rebecca Grainger; Suleman Bhana; Wendy Costello; Zachary S Wallace; Jinoos Yazdany Journal: ACR Open Rheumatol Date: 2022-07-22
Authors: Víctor Moreno-Torres; Carmen de Mendoza; Susana Mellor-Pita; María Martínez-Urbistondo; Pedro Durán-Del Campo; Pablo Tutor-Ureta; José-Manuel Vázquez-Comendador; Jorge Calderón-Parra; Elena Múñez-Rubio; Antonio Ramos-Martínez; Ana Fernández-Cruz; Raquel Castejón; Juan-Antonio Vargas-Nuñez Journal: Viruses Date: 2022-07-26 Impact factor: 5.818